Free Trial

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

Voyager Therapeutics logo with Medical background

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has received an average recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.39.

VYGR has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th.

Read Our Latest Stock Analysis on VYGR

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after purchasing an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management lifted its stake in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares during the period. CWM LLC boosted its holdings in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after buying an additional 9,376 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics during the fourth quarter worth about $60,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Up 4.6%

Shares of Voyager Therapeutics stock traded up $0.14 on Friday, hitting $3.18. The stock had a trading volume of 352,932 shares, compared to its average volume of 481,191. The company's 50 day moving average price is $3.20 and its 200 day moving average price is $4.00. The stock has a market cap of $175.98 million, a price-to-earnings ratio of -2.18 and a beta of 0.85. Voyager Therapeutics has a 52-week low of $2.65 and a 52-week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. Analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

About Voyager Therapeutics

(Get Free Report

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Featured Stories

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Should You Invest $1,000 in Voyager Therapeutics Right Now?

Before you consider Voyager Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.

While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines